GlobeNewswire Inc.·Mar 23·The Rosen Law FirmHub Group Restates 2025 Financials After Accounting Error; Stock Plunges 18.3%$HUBG tumbled 18.3% after revealing accounting errors in Q1-Q3 2025 results, understating transportation costs and payables. HUBGsecurities fraudclass action lawsuit
GlobeNewswire Inc.·Mar 23·Rosen Law FirmELWT Plunges on Accounting Restatement; Class Action Investigation LaunchedElauwit Connection ($ELWT) stock fell 6.8% after disclosing revenue recognition errors in its Q3 2025 filing. Securities litigation firm investigating potential class action claims. ELWTsecurities fraudclass action lawsuit
GlobeNewswire Inc.·Mar 23·Rosen Law FirmRosen Law Firm Files Class Action Against ODDITY Tech Over Alleged Ad Algorithm MisstatementsRosen Law Firm launches securities class action against ODDITY Tech ($ODD) for allegedly misleading investors about algorithm changes affecting customer acquisition costs. ODDsecurities fraudclass action lawsuit
Benzinga·Mar 23·Chris KatjeTrump's Iran Strikes Trigger Approval Slump as Markets Tumble on Geopolitical RiskTrump's approval rating falls to 42% after Iran military strikes. Voters oppose action; S&P 500 drops below $650 amid Middle East tensions and oil price surge. SPYoil pricesstock market decline
GlobeNewswire Inc.·Mar 23·NaGAP Refinances $1.12B Maturing Bonds Through Scotiabank Credit FacilityGrupo Aeroportuario del Pacífico refinances maturing bond certificates worth Ps.1,120 million through new 12-month Scotiabank facility at TIIE Funding plus 44 basis points. PACcredit facilitydebt refinancing
GlobeNewswire Inc.·Mar 23·Not SpecifiediDox.ai Launches Guardrail Platform to Combat AI Agent Security VulnerabilitiesiDox.ai launches Guardrail AI governance platform with real-time monitoring to prevent autonomous agent security vulnerabilities like those exposed by OpenClaw research. NVDAAI agentscompliance
GlobeNewswire Inc.·Mar 23·Rosen Law FirmREGENXBIO Faces Securities Lawsuit Over Gene Therapy Trial DisclosuresRosen Law Firm recruits investors for securities class action against REGENXBIO over alleged RGX-111 gene therapy misstatements. Lead plaintiff deadline: April 14, 2026. RGNXsecurities class actionmaterial misstatement
GlobeNewswire Inc.·Mar 23·FiverrFiverr's AI Video Hub Disrupts Hollywood Model With Budget-Friendly DirectorsFiverr launches AI Video Hub with independent directors delivering studio-quality content cheaper and faster than traditional Hollywood, capitalizing on 66% surge in AI video creation demand. FVRRcost reductionAI tools
GlobeNewswire Inc.·Mar 23·Rosen Law FirmSecurities Lawsuit Targets Paysafe Over Alleged Misstatements; Investors Face Filing DeadlineRosen Law Firm files securities class action against Paysafe Limited, alleging false statements about business operations and financial performance. Investors must act before lead plaintiff deadline. RGNXODDPSFEsecurities class actionlead plaintiff deadline
The Motley Fool·Mar 23·Lawrence NgaPalantir's Path to AI Dominance: The Bull Case for Enterprise OS CrownPalantir could become the operating system for enterprise AI through its integrated platform ecosystem, potentially achieving infrastructure-level economics similar to Microsoft over three years. MSFTPLTRvaluationenterprise AI
GlobeNewswire Inc.·Mar 23·NaGalapagos and Gilead Team Up on Breakthrough T Cell Engager for Autoimmune DiseasesGalapagos and Gilead plan to jointly develop an Ouro T cell engager for autoimmune diseases, splitting acquisition costs while Galapagos leads development and Gilead commercializes, freeing $500M in Galapagos cash. GILDGLPGautoimmune diseasesorphan drug designation
GlobeNewswire Inc.·Mar 23·NaGalapagos, Gilead in Advanced Talks on T-Cell Therapy PartnershipGalapagos and Gilead are in advanced partnership talks for a first-in-class T-cell engager for autoimmune diseases, with 50% cost-sharing and €500 million capital freed for Galapagos. GILDGLPGstrategic partnershipclinical development
GlobeNewswire Inc.·Mar 23·Kirby Mcinerney Llp$STLA Plunges 23.7% as Law Firm Probes Stellantis for Securities ViolationsLaw firm investigates Stellantis for potential securities violations after €22.2 billion charge announcement triggers 23.7% stock plunge to $7.28. STLAsecurities investigationstock price decline
The Motley Fool·Mar 23·Eric VolkmanArm Holdings Surges on AI Chiplet Ambitions Ahead of Product RevealArm Holdings stock rises 3% ahead of March 24 product event as Morgan Stanley predicts AI chiplet announcement targeting cloud computing customers. MSFTAMZNARMcloud computingmorgan-stanley
The Motley Fool·Mar 23·Emma NewberyAirlines Soar as Geopolitical Tensions Ease, Oil Prices DropAirlines rally on easing Iran tensions and declining oil prices. AAL up 3.64% to $10.81, though down 16% monthly amid persistent volatility. DALUALAALoil pricesgeopolitical risk
GlobeNewswire Inc.·Mar 23·Rosen Law FirmKyndryl Faces Securities Class Action Over False Financial DisclosuresRosen Law Firm urges Kyndryl investors to retain counsel before April 13, 2026 deadline in securities class action over false financial disclosures. KDsecurities class actionlead plaintiff deadline
Benzinga·Mar 23·Chris KatjeCongressman Dumps Warner Bros. Discovery Stock Despite 150% Gain Amid Merger ReviewRep. Pfluger sells Warner Bros. Discovery stock despite 150% annual gain amid DOJ review of Paramount-Skydance merger. NFLXWBDParamount SkydanceWarner Bros. Discovery
GlobeNewswire Inc.·Mar 23·Faruqi & Faruqi, LlpCoty Faces Securities Lawsuit Over Undisclosed Business DeteriorationSecurities class action filed against $COTY for failing to disclose weakness in beauty and fragrance segments. Stock fell 22% following disappointing Q2 results and guidance withdrawal. COTYstock declineearnings miss
The Motley Fool·Mar 23·Todd ShriberBlue Owl Crisis Triggers BDC Selloff—But BIZD Offers Bargain for Risk-Tolerant InvestorsVanEck BDC Income ETF down 12% in 2026 as private credit turmoil spreads. BDCs trade at steep discounts to book value, potentially presenting opportunity. OBDCBIZDhigh-yield ETFprivate credit
Benzinga·Mar 23·Not SpecifiedOutlook Therapeutics Launches Capital Raise Through Public Stock OfferingOutlook Therapeutics launches best-efforts public offering of stock and warrants with H.C. Wainwright as placement agent, subject to market conditions. OTLKwarrantspublic offering